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Antibody-dependent enhancement (ADE) is a mechanism
by which viruses, such as dengue, HIV and Ebola, gain
entry into some target cells through the use of host anti-
viral humoral immune responses [1]. Here, we studied the
ability of severe acute respiratory syndrome coronavirus
(SARS-CoV) [2] to use ADE mechanisms to enhance its
infectivity towards cells of the hematopoietic lineage.
We found that heat-inactivated immune serum from
rodents vaccinated with recombinant native full-length
Spike protein trimers [3] triggered infection of human
immune cells (monocytic and B cell lines) by SARS-CoV
Spike pseudotyped particle (SARS-CoVpp). The occur-
rence of antibody-mediated infection of human Raji B
cells was further investigated by using live SARS-CoV.
Similarly to results obtained with the SARS-CoVpp, only
anti-SARS-CoV Spike serum, but not mock immune-
serum, induced a massive increase of SARS-CoV viral
genes (ORF1b and Nucleocapsid) and viral proteins
(Membrane and Nucleocapsid) in Raji B cells. As
revealed by immunostaining, only a relatively low, how-
ever significant percentage of the Raji cells get infected
by antibody-mediated infection and did not allow direct
assessment of productive replication by conventional
cytopathic assays and TCID50 titration.
Taken together, our data suggested that SARS-CoV
is able to enter human immune cells via an antibody-
mediated pathway and immunological consequences of
such infection are under investigation (productive
replication, cytokines secretion profile and cell death
etc). Our data raise reasonable concerns regarding the
u s eo fS A R S - C o Vv a c c i n ei nh u m a n sa n dp a v e
the way to further studies focusing on the role of
immune-mediated infection phenomenon during SARS
pathogenesis.
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